LVIVO-TaVec400 product is named as an intervention in 2 current clinical trials in our China register. None are recruiting at the moment. All registered phases are Phase EARLY_PHASE1. The sponsor with the most trials is Institute of Hematology & Blood Diseases Hospital, China (1). The most-studied condition is Multiple Myeloma (MM).
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Multiple Myeloma๏ผLB2505-0001๏ผ
NCT07399444 · ClinicalTrials.gov ↗ · Multiple Myeloma (MM)
|
Phase EARLY_PHASE1 | Not yet open | Institute of Hematology & Blood Diseases Hospital, China | China |
|
A Clinical Study to Evaluate LVIVO-TaVec400 for the Treatment of Relapsed/Refractory Autoimmune Diseases
NCT07583030 · ClinicalTrials.gov ↗ · Relapsed/Refractory Systemic Lupus Erythematosus (r/r SLE), Relapsed/Refractory IgG4-Related Disease (r/r IgG4-RD), Progressive Multiple Sclerosis (PMS)
|
Phase EARLY_PHASE1 | Not yet open | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 0 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name LVIVO-TaVec400 product as a drug or biological intervention, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.
Not at the moment. None of the 2 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Institute of Hematology & Blood Diseases Hospital, China (1) and Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how LVIVO-TaVec400 product works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how LVIVO-TaVec400 product works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists LVIVO-TaVec400 product (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 26 Sep 2026.